PL2753606T3 - Pirymidyny jako blokery kanałów sodowych - Google Patents
Pirymidyny jako blokery kanałów sodowychInfo
- Publication number
- PL2753606T3 PL2753606T3 PL12770217T PL12770217T PL2753606T3 PL 2753606 T3 PL2753606 T3 PL 2753606T3 PL 12770217 T PL12770217 T PL 12770217T PL 12770217 T PL12770217 T PL 12770217T PL 2753606 T3 PL2753606 T3 PL 2753606T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrimidines
- sodium channel
- channel blockers
- blockers
- sodium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161530678P | 2011-09-02 | 2011-09-02 | |
US201261651611P | 2012-05-25 | 2012-05-25 | |
PCT/IB2012/001871 WO2013030665A1 (en) | 2011-09-02 | 2012-08-31 | Pyrimidines as sodium channel blockers |
EP12770217.3A EP2753606B1 (en) | 2011-09-02 | 2012-08-31 | Pyrimidines as sodium channel blockers |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2753606T3 true PL2753606T3 (pl) | 2018-02-28 |
Family
ID=47010645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12770217T PL2753606T3 (pl) | 2011-09-02 | 2012-08-31 | Pirymidyny jako blokery kanałów sodowych |
Country Status (19)
Country | Link |
---|---|
US (4) | US9163008B2 (pl) |
EP (2) | EP2753606B1 (pl) |
JP (2) | JP5941546B2 (pl) |
AR (1) | AR088029A1 (pl) |
AU (1) | AU2012300567B2 (pl) |
CA (1) | CA2846463C (pl) |
CY (1) | CY1119327T1 (pl) |
DK (1) | DK2753606T3 (pl) |
ES (1) | ES2643235T3 (pl) |
HR (1) | HRP20171389T1 (pl) |
HU (1) | HUE034925T2 (pl) |
LT (1) | LT2753606T (pl) |
ME (1) | ME02873B (pl) |
PL (1) | PL2753606T3 (pl) |
PT (1) | PT2753606T (pl) |
RS (1) | RS56342B1 (pl) |
SI (1) | SI2753606T1 (pl) |
TW (1) | TW201331186A (pl) |
WO (1) | WO2013030665A1 (pl) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9212139B2 (en) | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
WO2012007836A1 (en) | 2010-07-16 | 2012-01-19 | Purdue Pharma .Lp. | Pyridine compounds as sodium channel blockers |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
JP2013540130A (ja) | 2010-10-05 | 2013-10-31 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのキナゾリン化合物 |
JP2014500303A (ja) | 2010-12-22 | 2014-01-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としての置換ピリジン |
EP2753606B1 (en) | 2011-09-02 | 2017-07-05 | Purdue Pharma LP | Pyrimidines as sodium channel blockers |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
WO2014072809A2 (en) | 2012-11-09 | 2014-05-15 | Purdue Pharma L.P. | Benzomorphan analogs and the use thereof |
EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
JP6110516B2 (ja) * | 2013-03-04 | 2017-04-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリミジンカルボキサミド |
EP3666274A1 (en) | 2013-03-15 | 2020-06-17 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
MA38661A1 (fr) | 2013-06-27 | 2017-03-31 | Pfizer | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9359330B2 (en) * | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
PT3060550T (pt) * | 2013-10-21 | 2019-08-27 | Merck Patent Gmbh | Compostos de heteroarilo como inibidores de btk e utilizações dos mesmos |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
WO2015089361A1 (en) * | 2013-12-13 | 2015-06-18 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
EP3083606B1 (en) | 2013-12-20 | 2020-10-28 | Purdue Pharma LP | Pyrimidines and use thereof |
WO2015099841A1 (en) * | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Indazoles and use thereof |
US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
EP3089978B1 (en) | 2013-12-30 | 2018-08-29 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
US10047075B2 (en) | 2014-01-24 | 2018-08-14 | Purdue Pharma L.P. | Pyridines and pyrimidines and use thereof |
WO2015123398A1 (en) | 2014-02-12 | 2015-08-20 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
JP6386088B2 (ja) | 2014-05-06 | 2018-09-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ベンゾモルファン類似体及びその使用 |
MA40170A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés hétérocycliques de morphinan et leur utilisation |
CA2951697A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Azamophinan derivatives and use thereof |
CA2977367A1 (en) * | 2015-02-19 | 2016-08-25 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
US10745402B2 (en) | 2017-01-02 | 2020-08-18 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
JP7114394B2 (ja) * | 2017-08-18 | 2022-08-08 | 住友化学株式会社 | 化合物、レジスト組成物及びレジストパターンの製造方法 |
JP2021512935A (ja) | 2018-02-12 | 2021-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 疼痛を処置する方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL260746A (pl) * | 1960-02-02 | |||
AU6111796A (en) | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor |
US5739127A (en) * | 1996-11-08 | 1998-04-14 | Bayer Aktiengesellschaft | 2,4'-bridged bis-2,4-diaminoquinazolines |
JP2001526648A (ja) | 1997-04-22 | 2001-12-18 | コセンシス・インコーポレイテッド | 炭素環及びヘテロ環で置換されたセミカルバゾン及びチオセミカルバゾン、及びその使用 |
IL136044A (en) | 1997-11-21 | 2005-08-31 | Euro Celtique Sa | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same |
US6281211B1 (en) | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
NZ514756A (en) | 1999-03-26 | 2004-04-30 | Euro Celtique S | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
ATE303162T1 (de) | 1999-04-09 | 2005-09-15 | Euro Celtique Sa | Natrium kanalblocker zusammensetzungen und deren verwendung |
AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
BR0108819A (pt) | 2000-03-24 | 2002-12-10 | Euro Celtique Sa | Pirazóis triazóis e tetrazóis substituìdos de arila, e o uso dos mesmos |
US6335354B2 (en) | 2000-03-31 | 2002-01-01 | Cocensys Inc. | Aminopyridines and methods of using thereof |
MXPA04000411A (es) | 2001-07-16 | 2004-03-18 | Euro Celtique Sa | Tiazolidinonas arilo sustituidas y uso de las mismas. |
AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
ATE355064T1 (de) * | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
MXPA04008901A (es) | 2002-03-13 | 2004-11-26 | Euro Celtique Sa | Pirimidinas arilo sustituidas y el uso de las mismas. |
WO2003080060A1 (en) * | 2002-03-20 | 2003-10-02 | Schering Aktiengesellschaft | Substituted piperazine antithrombotic pai-1 inhibitors |
US6675042B2 (en) | 2002-04-15 | 2004-01-06 | Charles D. Swerdlow | Defibrillation shock strength determination technology |
JP2006504660A (ja) | 2002-07-31 | 2006-02-09 | ユーロ−セルティーク エス.エイ. | アリール置換ベンゾイミダゾール類およびナトリウムチャネルブロッカーとしてのそれらの使用 |
KR20050026023A (ko) | 2002-07-31 | 2005-03-14 | 유로-셀티큐 에스.에이. | 아릴 치환된 히단토인 화합물 및 그들의 나트륨 채널차단제로서의 용도 |
US20040152696A1 (en) | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
TWI339204B (en) | 2002-11-21 | 2011-03-21 | Novartis Vaccines & Diagnostic | Small molecule pi 3-kinase inhibitors and methods of their use |
WO2004052862A1 (ja) * | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
US20060293339A1 (en) * | 2003-03-24 | 2006-12-28 | Chakravarty Prasun K | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
WO2004087679A1 (en) * | 2003-04-01 | 2004-10-14 | Aponetics Ag | 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
TWI355894B (en) * | 2003-12-19 | 2012-01-11 | Du Pont | Herbicidal pyrimidines |
US20050282824A1 (en) | 2004-05-07 | 2005-12-22 | Xiaobing Li | Substituted pyrimidines as inhibitors of bacterial type III protein secretion systems |
EP1652831A4 (en) | 2004-06-25 | 2009-07-01 | Ibiden Co Ltd | PROCESS FOR PRODUCING POROUS BODIES, POROUS BODIES, AND ALVEOLAR STRUCTURAL BODY |
TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
EP1809290A2 (en) * | 2004-11-03 | 2007-07-25 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
TW200640877A (en) * | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
CN101223146A (zh) | 2005-05-24 | 2008-07-16 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
CA2617042A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
WO2007089382A2 (en) | 2006-01-03 | 2007-08-09 | Pharmagic, Inc. | Nanofactory compositions and methods of making and using nanofactories |
AU2007204208A1 (en) * | 2006-01-11 | 2007-07-19 | Astrazeneca Ab | Morpholino pyrimidine derivatives and their use in therapy |
KR101435231B1 (ko) * | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
WO2008125833A1 (en) * | 2007-04-12 | 2008-10-23 | Piramed Limited | Pharmaceutical compounds |
JP2010533161A (ja) * | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物−946 |
WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
CA2732618A1 (en) * | 2008-07-30 | 2010-02-04 | Ranbaxy Laboratories Limited | Pyrrole carboxylic acid derivatives as antibacterial agents |
JP2012501962A (ja) * | 2008-09-10 | 2012-01-26 | 田辺三菱製薬株式会社 | 芳香族含窒素六員環化合物及びその使用 |
CA2783209C (en) | 2009-12-22 | 2017-03-14 | Msd Oss B.V. | Amino-heteroaryl derivatives as hcn blockers |
TWI555746B (zh) * | 2009-12-28 | 2016-11-01 | 財團法人生物技術開發中心 | 作為mTOR及PI3K抑制劑之新穎嘧啶化合物 |
CA2789711C (en) * | 2010-02-17 | 2014-08-05 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
EP2382865A1 (de) | 2010-04-28 | 2011-11-02 | Bayer CropScience AG | Synergistische Wirkstoffkombinationen |
US8877745B2 (en) * | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
US9212139B2 (en) | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
WO2012007836A1 (en) | 2010-07-16 | 2012-01-19 | Purdue Pharma .Lp. | Pyridine compounds as sodium channel blockers |
US9056832B2 (en) | 2010-09-17 | 2015-06-16 | Purdue Pharma L.P. | Pyridine compounds and the users thereof |
JP2013540130A (ja) | 2010-10-05 | 2013-10-31 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのキナゾリン化合物 |
GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
CN103415515B (zh) * | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
JP2014500303A (ja) | 2010-12-22 | 2014-01-09 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としての置換ピリジン |
EP2731941B1 (en) * | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
EP2753606B1 (en) * | 2011-09-02 | 2017-07-05 | Purdue Pharma LP | Pyrimidines as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
AU2013203824A1 (en) | 2012-03-16 | 2013-10-03 | Purdue Pharma L.P. | Substituted pyridines and pryimidines as sodium channel blockers |
US9718865B2 (en) | 2012-07-27 | 2017-08-01 | Purdue Pharma L.P. | Sodium channel blocking peptides and the use thereof |
EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
JP6110516B2 (ja) * | 2013-03-04 | 2017-04-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリミジンカルボキサミド |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
US9346802B2 (en) * | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
EP3666274A1 (en) * | 2013-03-15 | 2020-06-17 | Purdue Pharma LP | Carboxamide derivatives and use thereof |
EA201591532A1 (ru) * | 2013-03-15 | 2016-03-31 | Эпизим, Инк. | Ингибиторы carm1 и их применение |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
EP3083606B1 (en) | 2013-12-20 | 2020-10-28 | Purdue Pharma LP | Pyrimidines and use thereof |
WO2015099841A1 (en) * | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Indazoles and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
CA2977367A1 (en) | 2015-02-19 | 2016-08-25 | Purdue Pharma L.P. | Methods and compositions for decreasing gastric emptying |
-
2012
- 2012-08-31 EP EP12770217.3A patent/EP2753606B1/en active Active
- 2012-08-31 DK DK12770217.3T patent/DK2753606T3/en active
- 2012-08-31 AR ARP120103243A patent/AR088029A1/es unknown
- 2012-08-31 AU AU2012300567A patent/AU2012300567B2/en active Active
- 2012-08-31 LT LTEP12770217.3T patent/LT2753606T/lt unknown
- 2012-08-31 ES ES12770217.3T patent/ES2643235T3/es active Active
- 2012-08-31 TW TW101131836A patent/TW201331186A/zh unknown
- 2012-08-31 SI SI201231060T patent/SI2753606T1/sl unknown
- 2012-08-31 PL PL12770217T patent/PL2753606T3/pl unknown
- 2012-08-31 ME MEP-2017-219A patent/ME02873B/me unknown
- 2012-08-31 PT PT127702173T patent/PT2753606T/pt unknown
- 2012-08-31 HU HUE12770217A patent/HUE034925T2/en unknown
- 2012-08-31 CA CA2846463A patent/CA2846463C/en active Active
- 2012-08-31 WO PCT/IB2012/001871 patent/WO2013030665A1/en active Application Filing
- 2012-08-31 US US14/342,054 patent/US9163008B2/en active Active
- 2012-08-31 JP JP2014527753A patent/JP5941546B2/ja active Active
- 2012-08-31 EP EP17179551.1A patent/EP3255041A1/en not_active Withdrawn
- 2012-08-31 RS RS20170917A patent/RS56342B1/sr unknown
-
2015
- 2015-09-23 US US14/862,396 patent/US9656968B2/en active Active
-
2016
- 2016-05-20 JP JP2016100979A patent/JP6239688B2/ja active Active
-
2017
- 2017-05-04 US US15/586,963 patent/US10059675B2/en active Active
- 2017-09-11 CY CY20171100955T patent/CY1119327T1/el unknown
- 2017-09-14 HR HRP20171389TT patent/HRP20171389T1/hr unknown
-
2018
- 2018-06-01 US US15/996,053 patent/US10774050B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2012300567B2 (en) | 2016-03-10 |
WO2013030665A1 (en) | 2013-03-07 |
CA2846463C (en) | 2017-10-24 |
US9163008B2 (en) | 2015-10-20 |
JP2016175940A (ja) | 2016-10-06 |
JP6239688B2 (ja) | 2017-11-29 |
CY1119327T1 (el) | 2018-02-14 |
US20170298027A1 (en) | 2017-10-19 |
HUE034925T2 (en) | 2018-03-28 |
US20140303139A1 (en) | 2014-10-09 |
AU2012300567A1 (en) | 2013-05-02 |
LT2753606T (lt) | 2017-09-25 |
ME02873B (me) | 2018-04-20 |
JP5941546B2 (ja) | 2016-06-29 |
PT2753606T (pt) | 2017-10-02 |
TW201331186A (zh) | 2013-08-01 |
US10059675B2 (en) | 2018-08-28 |
SI2753606T1 (sl) | 2017-10-30 |
EP2753606A1 (en) | 2014-07-16 |
HRP20171389T1 (hr) | 2017-11-03 |
US20160024022A1 (en) | 2016-01-28 |
CA2846463A1 (en) | 2013-03-07 |
US10774050B2 (en) | 2020-09-15 |
JP2014525431A (ja) | 2014-09-29 |
EP3255041A1 (en) | 2017-12-13 |
EP2753606B1 (en) | 2017-07-05 |
ES2643235T3 (es) | 2017-11-21 |
US9656968B2 (en) | 2017-05-23 |
DK2753606T3 (en) | 2017-10-02 |
AR088029A1 (es) | 2014-05-07 |
RS56342B1 (sr) | 2017-12-29 |
US20190002412A1 (en) | 2019-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171389T1 (hr) | Pirimidini kao blokatori natrijevog kanala | |
ZA201303780B (en) | Substituted pyridines as sodium channel blockers | |
IL225516A0 (en) | Quinazoline compounds as sodium channel blockers | |
ZA201205126B (en) | Voltage-gated sodium channel blockers | |
EP2711605A4 (en) | LAMP | |
HK1200114A1 (en) | Sodium channel blockers reduce glucagon secretion | |
EP2795187A4 (en) | LIGHT GUIDE FOR LUMINAIRE | |
GB201400060D0 (en) | Enhancing communication | |
IL229447A0 (en) | History of amine as potassium channel blockers | |
IL229410A0 (en) | Metabolized pyridopyrazines as novel cyk inhibitors | |
HK1184599A1 (zh) | 光下行鏈路系統 | |
EP2661179A4 (en) | COMPOSITION WITH REDUCED SODIUM CONTENT | |
EP2669731A4 (en) | GLASSES | |
GB201102129D0 (en) | Recessed light fitting | |
EP2758058A4 (en) | SUBSTITUTED PYRIMIDINES | |
PL2780295T3 (pl) | Szyba hydrofobowa | |
GB2490370B (en) | Multipoint communications | |
AU339253S (en) | Light | |
EP2696519A4 (en) | OPTICAL RECEIVER | |
EP2758059A4 (en) | SUBSTITUTED PYRIMIDINES | |
ZA201309533B (en) | Voltage-gated sodium channel blockers | |
ZA201402298B (en) | Heterocyclylpyri (mi)dinylpyrazole as fungicidals | |
PL2518249T3 (pl) | Zespół oszklenia | |
GB201120262D0 (en) | Simultaneous demultiplexing | |
GB2496315B (en) | Multiplex optical assembly |